Difference between revisions of "Main Page"
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) |
||
Line 52: | Line 52: | ||
|style="background-color:#deebf7"|[[Melanoma,_KIT-mutated|Melanoma, KIT-mutated]] | |style="background-color:#deebf7"|[[Melanoma,_KIT-mutated|Melanoma, KIT-mutated]] | ||
|style="background-color:#deebf7"|[[Melanoma,_NRAS-mutated|Melanoma, NRAS-mutated]] | |style="background-color:#deebf7"|[[Melanoma,_NRAS-mutated|Melanoma, NRAS-mutated]] | ||
− | |style="background-color:#deebf7"|[[Merkel cell carcinoma]] | + | |style="background-color:#deebf7"|[[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]] |
|style="background-color:#deebf7"|[[Uveal melanoma]] | |style="background-color:#deebf7"|[[Uveal melanoma]] | ||
|- | |- | ||
Line 58: | Line 58: | ||
|- | |- | ||
|style="background-color:#deebf7"|[[Adrenocortical carcinoma]] | |style="background-color:#deebf7"|[[Adrenocortical carcinoma]] | ||
− | |style="background-color:#deebf7"|[[Neuroendocrine tumor]] | + | |style="background-color:#deebf7"|[[Neuroendocrine tumor|Neuroendocrine tumor (NET)]] |
|style="background-color:#deebf7"|[[Pancreatic NET]] | |style="background-color:#deebf7"|[[Pancreatic NET]] | ||
|style="background-color:#deebf7"|[[Pheochromocytoma]] | |style="background-color:#deebf7"|[[Pheochromocytoma]] | ||
Line 64: | Line 64: | ||
|style="background-color:#deebf7"|[[Thyroid cancer]] | |style="background-color:#deebf7"|[[Thyroid cancer]] | ||
|style="background-color:#deebf7"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]] | |style="background-color:#deebf7"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]] | ||
− | |style="background-color:#deebf7"|[[Thyroid cancer, medullary|Medullary thyroid cancer]] | + | |style="background-color:#deebf7"|[[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]] |
|style="background-color:#deebf7"|[[Thyroid_cancer,_BRAF-mutated|Thyroid cancer, BRAF-mutated]] | |style="background-color:#deebf7"|[[Thyroid_cancer,_BRAF-mutated|Thyroid cancer, BRAF-mutated]] | ||
|- | |- | ||
Line 79: | Line 79: | ||
|style="width: 25%; background-color:#deebf7"|[[Colon cancer, RAS wild-type]] | |style="width: 25%; background-color:#deebf7"|[[Colon cancer, RAS wild-type]] | ||
|- | |- | ||
− | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer|Colorectal cancer (CRC)]] |
− | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, BRAF-mutated]] | + | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, BRAF-mutated|CRC, BRAF-mutated]] |
− | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, HER2-positive]] | + | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, HER2-positive|CRC, HER2-positive]] |
− | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, MSI-H or dMMR]] | + | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, MSI-H or dMMR|CRC, MSI-H or dMMR]] |
|- | |- | ||
− | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, RAS wild-type]] | + | |style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, RAS wild-type|CRC, RAS wild-type]] |
|style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]] | |style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]] | ||
|style="width: 25%; background-color:#deebf7"|[[Esophageal adenocarcinoma]] | |style="width: 25%; background-color:#deebf7"|[[Esophageal adenocarcinoma]] | ||
Line 98: | Line 98: | ||
|style="width: 25%; background-color:#deebf7"|[[Cholangiocarcinoma]] | |style="width: 25%; background-color:#deebf7"|[[Cholangiocarcinoma]] | ||
|style="width: 25%; background-color:#deebf7"|[[Gallbladder cancer]] | |style="width: 25%; background-color:#deebf7"|[[Gallbladder cancer]] | ||
− | |style="width: 25%; background-color:#deebf7"|[[Hepatocellular carcinoma]] | + | |style="width: 25%; background-color:#deebf7"|[[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]] |
|style="width: 25%; background-color:#deebf7"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]] | |style="width: 25%; background-color:#deebf7"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]] | ||
|- | |- | ||
|style="width: 25%; background-color:#deebf7"|[[Periampullary adenocarcinoma]] | |style="width: 25%; background-color:#deebf7"|[[Periampullary adenocarcinoma]] | ||
− | |style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer|Pancreatic adenocarcinoma]] |
− | |style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer, BRCA-mutated]] | + | |style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer, BRCA-mutated|Pancreateic adenocarcinoma, BRCA-mutated]] |
|style="width: 25%; background-color:#deebf7"|[[Pancreatic NET]] | |style="width: 25%; background-color:#deebf7"|[[Pancreatic NET]] | ||
|- | |- | ||
Line 138: | Line 138: | ||
|- | |- | ||
|style="background-color:#deebf7"|[[Head and neck cancer]] | |style="background-color:#deebf7"|[[Head and neck cancer]] | ||
− | |style="background-color:#deebf7"|[[Nasopharyngeal carcinoma]] | + | |style="background-color:#deebf7"|[[Nasopharyngeal carcinoma|Nasopharyngeal carcinoma (NPC)]] |
|style="background-color:#deebf7"|[[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]] | |style="background-color:#deebf7"|[[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
|- | |- | ||
Line 150: | Line 145: | ||
|- | |- | ||
|style="background-color:#deebf7"|[[Anaplastic glioma]] | |style="background-color:#deebf7"|[[Anaplastic glioma]] | ||
− | |style="background-color:#deebf7"|[[Glioblastoma]] | + | |style="background-color:#deebf7"|[[Glioblastoma|Glioblastoma (GBM)]] |
|style="background-color:#deebf7"|[[Low-grade glioma]] | |style="background-color:#deebf7"|[[Low-grade glioma]] | ||
|style="background-color:#deebf7"|[[Meningioma]] | |style="background-color:#deebf7"|[[Meningioma]] | ||
Line 171: | Line 166: | ||
|style="background-color:#deebf7"|[[Ewing sarcoma]] | |style="background-color:#deebf7"|[[Ewing sarcoma]] | ||
|- | |- | ||
− | |style="background-color:#deebf7"|[[Kaposi sarcoma]] | + | |style="background-color:#deebf7"|[[Kaposi sarcoma|Kaposi sarcoma (KS)]] |
− | |style="background-color:#deebf7"|[[Leiomyosarcoma]] | + | |style="background-color:#deebf7"|[[Leiomyosarcoma|Leiomyosarcoma (LMS)]] |
|style="background-color:#deebf7"|[[Liposarcoma]] | |style="background-color:#deebf7"|[[Liposarcoma]] | ||
|style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]] | |style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]] | ||
Line 178: | Line 173: | ||
|style="background-color:#deebf7"|[[Osteosarcoma]] | |style="background-color:#deebf7"|[[Osteosarcoma]] | ||
|style="background-color:#deebf7"|[[PEComa]] | |style="background-color:#deebf7"|[[PEComa]] | ||
− | |style="background-color:#deebf7"|[[Rhabdomyosarcoma]] | + | |style="background-color:#deebf7"|[[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]] |
|style="background-color:#deebf7"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS)]] | |style="background-color:#deebf7"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS)]] | ||
|- | |- | ||
Line 188: | Line 183: | ||
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Thoracic Oncology''' | |colspan="4" style="font-size:125%; background-color:#6baed6"|'''Thoracic Oncology''' | ||
|- | |- | ||
− | |||
|style="background-color:#deebf7"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]] | |style="background-color:#deebf7"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]] | ||
|style="background-color:#deebf7"|[[Non-small cell lung cancer, nonsquamous|NSCLC, nonsquamous]] | |style="background-color:#deebf7"|[[Non-small cell lung cancer, nonsquamous|NSCLC, nonsquamous]] | ||
|style="background-color:#deebf7"|[[Non-small cell lung cancer, squamous|NSCLC, squamous]] | |style="background-color:#deebf7"|[[Non-small cell lung cancer, squamous|NSCLC, squamous]] | ||
+ | |style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_ALK-positive|NSCLC, ALK-positive]] | ||
|- | |- | ||
− | |||
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_BRAF-mutated|NSCLC, BRAF-mutated]] | |style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_BRAF-mutated|NSCLC, BRAF-mutated]] | ||
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_EGFR-mutated|NSCLC, EGFR-mutated]] | |style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_EGFR-mutated|NSCLC, EGFR-mutated]] | ||
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_KRAS-mutated|NSCLC, KRAS-mutated]] | |style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_KRAS-mutated|NSCLC, KRAS-mutated]] | ||
+ | |style="background-color:#deebf7"|[[Non-small cell lung cancer, MET-mutated|NSCLC, MET-mutated]] | ||
|- | |- | ||
− | |||
|style="background-color:#deebf7"|[[Non-small cell lung cancer, RET-positive|NSCLC, RET-positive]] | |style="background-color:#deebf7"|[[Non-small cell lung cancer, RET-positive|NSCLC, RET-positive]] | ||
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_ROS1-positive|NSCLC, ROS1-positive]] | |style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_ROS1-positive|NSCLC, ROS1-positive]] | ||
|style="background-color:#deebf7"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]] | |style="background-color:#deebf7"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]] | ||
+ | |style="background-color:#deebf7"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]] | ||
|- | |- | ||
− | |||
|style="background-color:#deebf7"|[[Thymoma]] | |style="background-color:#deebf7"|[[Thymoma]] | ||
+ | |style="background-color:#deebf7"| | ||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
Line 220: | Line 215: | ||
|style="background-color:#deebf7"|[[TMB-H]] | |style="background-color:#deebf7"|[[TMB-H]] | ||
|- | |- | ||
− | |style="background-color:#deebf7"|[[Carcinoma of unknown primary]] | + | |style="background-color:#deebf7"|[[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]] |
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
Line 244: | Line 239: | ||
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]] | |style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]] | ||
|- | |- | ||
− | |style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm]] | + | |style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]] |
|style="background-color:#fee0d2"|[[CNS leukemia]] | |style="background-color:#fee0d2"|[[CNS leukemia]] | ||
|style="background-color:#fee0d2"| | |style="background-color:#fee0d2"| | ||
Line 256: | Line 251: | ||
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]] | |style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]] | ||
|- | |- | ||
− | |style="background-color:#fee0d2"|[[Myelodysplastic syndrome]] | + | |style="background-color:#fee0d2"|[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]] |
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]] | |style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]] | ||
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]] | |style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]] | ||
Line 298: | Line 293: | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]] | |style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]] | ||
− | |style="background-color:#fee0d2"|[[Plasma cell leukemia]] | + | |style="background-color:#fee0d2"|[[Plasma cell leukemia|Plasma cell leukemia (PCL)]] |
|style="background-color:#fee0d2"|[[POEMS syndrome]] | |style="background-color:#fee0d2"|[[POEMS syndrome]] | ||
|style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]] | |style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]] | ||
Line 326: | Line 321: | ||
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocyte disorders''' | |colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocyte disorders''' | ||
|- | |- | ||
− | |style="background-color:#fee0d2"|[[Erdheim-Chester disease]] | + | |style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]] |
|style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]] | |style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]] | ||
− | |style="background-color:#fee0d2"|[[Langerhans cell histiocytosis]] | + | |style="background-color:#fee0d2"|[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]] |
|style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]] | |style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]] | ||
|- | |- | ||
Line 356: | Line 351: | ||
|style="background-color:#e8d7b3"| | |style="background-color:#e8d7b3"| | ||
|- | |- | ||
− | |style="background-color:#e8d7b3"|[[Hodgkin lymphoma, pediatric | Hodgkin lymphoma]] | + | |style="background-color:#e8d7b3"|[[Hodgkin lymphoma, pediatric | Hodgkin lymphoma (HL)]] |
|style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]] | |style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]] | ||
|style="background-color:#e8d7b3"| | |style="background-color:#e8d7b3"| | ||
Line 393: | Line 388: | ||
|- | |- | ||
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]] | |style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]] | ||
− | |style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome]] | + | |style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]] |
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]] | |style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]] | |style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]] | ||
Line 418: | Line 413: | ||
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]] | |style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]] | ||
|style="background-color:#e5f5e0"|[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]] | |style="background-color:#e5f5e0"|[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]] | ||
− | |style="background-color:#e5f5e0"|[[Cold agglutinin disease]] | + | |style="background-color:#e5f5e0"|[[Cold agglutinin disease|Cold agglutinin disease (CAD)]] |
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]] | |style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]] | ||
|- | |- |
Revision as of 22:05, 17 September 2022
HemOnc.org - A Free Hematology/Oncology Reference
Regimens: 4,429 | Regimen variants: 6,545 | Studies: 6,196 | References: 7,061 |
---|
Solid Tumors | Malignant Hematology | Pediatrics | Transplant | Classical Hematology |
Links to all main disease pages
Pediatric Neoplasms | |||
---|---|---|---|
Pediatric CNS malignancies | |||
Low-grade glioma | High-grade glioma | Medulloblastoma | |
Pediatric hematologic neoplasms | |||
B-cell acute lymphoblastic leukemia (B-ALL) | B-ALL, Ph+ | T-cell acute lymphoblastic leukemia (T-ALL) | Acute myeloid leukemia (AML) |
Anaplastic large cell lymphoma (ALCL) | Chronic myeloid leukemia (CML) | Juvenile myelomonocytic leukemia (JMML) | |
Hodgkin lymphoma (HL) | Non-Hodgkin lymphoma (NHL) | ||
Pediatric solid tumors | |||
Epithelioid sarcoma | Ewing sarcoma | Hepatoblastoma | Neuroblastoma |
Osteosarcoma | Rhabdomyosarcoma | Wilms tumor |
Transplant | |||
---|---|---|---|
Stem cell mobilization | Allogeneic HSCT | Autologous HSCT | Graft versus host disease (GVHD) |
Additional Information
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.
Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.
Priorities of this project include:
- Creating a database of all approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology.
- Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles).
- Sample order sets and examples of supportive medications used with treatment regimens
- Aggregating useful links to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
- Creating, maintaining, and disseminating a formalized ontology of anticancer drugs and regimens.
Additional possibilities for this project may include:
- Creating synopses of pivotal clinical trials and regimens
- Prioritizing regimens by their efficacy and/or toxicity
- Capturing historical regimens that were standard-of-care prior to 2005
- Checklists for common clinical scenarios/diseases
- Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.